IDRx is a clinical-stage biopharmaceutical company that offers precision therapies to patients with gastrointestinal stromal tumors (GIST). Their pipeline includes small molecule tyrosine kinase inhibitors, IDRX-42 and IDRX-73, designed to target genetic drivers and drug-resistant mutations in GIST. IDRx aims to explore the potential of highly potent and selective therapies to address treatment limitations in precision cancer medicine. This company was founded by Alexis Borisy, Ben Auspitz, George Demetri MD, Nicholas Lydon Ph.D, and Robert Forrester in 2021 and is headquartered in Plymouth, MA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
08/07/2024 | Series B | $120.24MM | $xx.xx | $414.65MM | Andreessen Horowitz, Blackstone, Commodore Capital, Forge Life Science Partners, Merck, Nextech Invest, Nick Lydon, Ra Capital Management, Rock Springs Capital | |
Price per Share
$xx.xx
Shares Outstanding
18,667,528
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Blackstone, Commodore Capital, Forge Life Science Partners, Merck, Nextech Invest, Nick Lydon, Ra Capital Management, Rock Springs Capital
|
||||||
08/02/2022 | Series A-2 | $16.19MM | $xx.xx | $309.5MM | Andreessen Horowitz, Blueprint Medicines, Casdin Capital, Forge Life Science Partners, Nextech Invest | |
Price per Share
$xx.xx
Shares Outstanding
2,947,184
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Blueprint Medicines, Casdin Capital, Forge Life Science Partners, Nextech Invest
|
||||||
08/02/2022 | Series A-1 | $105.81MM | $xx.xx | $309.5MM | Andreessen Horowitz, Blueprint Medicines, Casdin Capital, Forge Life Science Partners, Nextech Invest | |
Price per Share
$xx.xx
Shares Outstanding
17,333,480
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Blueprint Medicines, Casdin Capital, Forge Life Science Partners, Nextech Invest
|